Aktienanalyse zu Zhengye Biotechnology Holding Ltd (ZYBT)ZYBTZhengye Biotechnology Holding Ltd

Zhengye Biotechnology Holding Ltd is a company mainly engaged in the research, development, manufacturing and sales of veterinary vaccines, with an emphasis on vaccines for livestock. The Company markets a diverse range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The Company owns about 44 veterinary vaccines in its product portfolio, which cover veterinary vaccines for livestock, including monovalent vaccine, polyvalent vaccine, combined vaccine and combined and polyvalent vaccine. The Company also engages in vaccines for treating livestock. The Company mainly conducts its business in the domestic market. The Company mainly conducts its business in the domestic and overseas market. It operates in the Healthcare sector.

Zhengye Biotechnology Holding Limited (ZYBT) is not a good buy right now due to its current price of $1.33, which is significantly below its 52-week high of $8.01, indicating a potential for further downside. Additionally, the RSI is at 36.326, suggesting that the stock is nearing oversold territory but has not yet reversed. The company has reported a gross margin of only 8.30% in the most recent quarter, which raises concerns about profitability and operational efficiency. The main risk is its negative net income margin of -89.05% in Q3 2025, indicating ongoing financial struggles that could impact future performance.